Seven and Eight Biopharma to present at the STING & TLR-Targeting Therapies Summit

  • May 25, 2021
  • Julie Ha

Robert Andtbacka, M.D., C.M., Chief Medical Officer, will give a presentation “BDB001, an Intravenously Delivered TLR7/8 Dual Agonist in Advanced Solid Tumors” during The 2nd STING- & TLR-Targeting Therapies Summit, on May 26, 2021. This presentation will highlight the TLR7/8 dual agonist program at Seven and Eight Biopharma and the recent clinical advances.

The conference is a forum for the development of drug candidates modulating the cGAS-STING pathway and Toll-Like Receptor (TLR) signaling both as monotherapies and as adjuvants in combinatorial approaches, and will be held virtually on May 25-27, 2021.

Dr. Andtbacka will make the presentation on May 26, at 5:15PM (EST)/2:15PM (PST), followed by a Speaker Q&A at 6:05PM (EST)/3:05PM (PST).